Innovations in the radiotherapy of non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 1, Issue 1, 2006, Pages 85-92

  Schild, Steven E ^a   Bogart, Jeffery A ^b  

^a MAYO CLINIC   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

CyberKnife; Heavy ion therapy; Intensity modulated radiation therapy; Lung cancer; New technology; Radiation therapy; Stereotactic radiotherapy; Tomotherapy

Indexed keywords

CARBOPLATIN; IRINOTECAN; NAVELBINE; PACLITAXEL;

BIOMEDICAL TECHNOLOGY ASSESSMENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DOSE RESPONSE; DOSIMETRY; ESOPHAGUS STRICTURE; HADRON; HEAVY ION RADIATION; HEMOPTYSIS; HUMAN; INFORMATION RETRIEVAL; INTENSITY MODULATED RADIATION THERAPY; LUNG NON SMALL CELL CANCER; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION PHYSICS; RADIATION PNEUMONIA; RADIOLOGY; REVIEW; STEREOTAXIC SURGERY; LUNG TUMOR; PATHOLOGY; RADIATION RESPONSE; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 34247863719     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200601000-00018     Document Type: Review

References (41)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002.CA Cancer J Clin 2006;55:74-108.
2. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004.CA Cancer J Clin 2004;54:8-29.
3. Videtic G, Vokes E, et al. The survival of patients treated for stage III non-small cell lung cancer in North America has increased during the past 25 years (Abstract 2557). The Proceedings of the American Society of Clinical Oncology. 2003:636.
4. Perez CA. Non-small cell carcinoma of the lung: dose-time parameters. Cancer Treatment Symp 1985;2:131-142.
5. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-1215.
6. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995;87:198-205.
7. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-530.
8. Le Chevalier T, Arriagada R, Tarayre M, et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma. J Natl Cancer Inst 1992;84:58.
9. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
10. Schild SE, Stella PJ, Geyer SM, et al. Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002;54:370-378.
11. Komaki R, Seiferheld W. Sequential vs. concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC): analysis of failures in a phase III study (RTOG 9410) (Abstract). Int J Radiat Oncol Biol Phys 2000;48:113.
12. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-2699.
13. Saunders M, Dische S, Barrett A, et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial: CHART Steering committee. Radiother Oncol 1999;52:137-148.
14. Belani CP, Wang W, Johnson DH, et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 2006;23:3760-3767.
15. Schild SE, Wong WW, Vora SA, et al. The long-term results of a pilot study of three times a day radiotherapy and escalating doses of daily cisplatin for locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006;62:1432-1437.
16. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991;83:417-423.
17. Mehta M, Scrimger R, Mackie R, et al. A new approach to dose escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001;49:23-33.
18. Bradley J, Graham MV, Winter K, et al. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2006;61:318-328.
19. Sim S, Rosenzweig KE, Schindelheim R, et al. Induction chemotherapy plus three-dimensional conformal radiation therapy in the definitive treatment of locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001;51:660-665.
20. Rosenzweig KE, Sim SE, Mychalczak B, et al. Elective nodal irradiation in the treatment of non-small-cell lung cancer with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 2001;50:681-685.
21. Belderbos JS, De Jaeger K, Heemsbergen WD, et al. First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. Radiother Oncol 2003;66:119-126.
22. Senan S, Burgers S, Samson MJ, et al. Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy. Int J Radiat Oncol Biol Phys 2002;54:999-1006.
23. Hayman JA, Martel MK, Ten Haken RK, et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol 2001;19:127-136.
24. Schild SE, Korte SM, Wong WW, et al. Treatment planning for dose escalation in non-small cell lung cancer (NSCLC). Med Dosim 2004;29:196-203.
25. Rosenzweig KE, Amols H, Ling CC. New radiotherapy technologies. Semin Surg Oncol 2003;21:190-195.
26. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999;45:323-329.
27. Blackstock AW, Socinski MA, Gu L. Initial pulmonary toxicity evaluation of chemoradiotherapy (CRT) utilizing 74 Gy 3-dimensional (3-D) thoracic radiation in stage III non-small cell lung cancer (NSCLC): a Cancer and Leukemia Group B (CALGB) randomized phase II trial (Abstract 7060). J Clin Oncol 2006;23 (Suppl):635s.
28. Socinski MA, Morris DE, Halle JS, et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. J Clin Oncol 2004;22:4341-4350.
29. Bradley JD, Graham M. Phase I results of RTOG L-0117: a phase I/II dose intensification study using 3DCRT and concurrent chemotherapy for patients with inoperable NSCLC (Abstract 7063). J Clin Oncol 2006;23 (Suppl):636s.
30. Schild S, McGinnis W, Graham D. Results of a phase I trial of concurrent chemotherapy and escalating doses of radiation for unresect-able non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2005;63:2(S1):S44.
31. Murshed H, Liu HH, Liao Z, et al. Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004;58:1258-1267.
32. Liu HH, Wang X, Dong L, et al. Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004;58:1268-1279.
33. Holloway CL, Robinson D, Murray B, et al. Results of a phase I study to dose escalate using intensity modulated radiotherapy guided by combined PET/CT imaging with induction chemotherapy for patients with non-small cell lung cancer. Radiother Oncol 2004;73:285-287.
34. Scrimger RA, Tome WA, Olivera GH, et al. Reduction in radiation dose to lung and other normal tissues using helical tomotherapy to treat lung cancer, in comparison to conventional field arrangements. Am J Clin Oncol 2003;26:70-78.
35. Rowell NP, Williams CJ. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable). Cochrane Database Syst Rev 2001:CD002935.
36. Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003;124:1946-1955.
37. Uematsu M, Shioda A, Suda A, et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys 2001;51:666-670.
38. Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004;101:1623-1631.
39. Whyte RI, Crownover R, Murphy MJ, et al. Stereotactic radiosurgery for lung tumors: preliminary report of a phase I trial. Ann Thorac Surg 2003;75:1097-1101.
40. Bush DA, Slater JD, Shin BB, et al. Hypofractionated proton beam radiotherapy for stage I lung cancer. Chest 2004;126:1198-1203.
41. Miyamoto T, Yamamoto N, Nishimura H, et al. Carbon ion radiotherapy for stage I non-small cell lung cancer. Radiother Oncol 2003;66:127-140.